Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
5 drugs in development
By Therapeutic Area
top 2
R&D Momentum
62/100
Pipeline Velocity
32/100
Trial Completion Rate
41/100
Pipeline Concentration
44/100
Pipeline Freshness
69/100
Strategic Signals
Activity
Last 14 days
Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Quantification and Purification of Circulating Prostasomes as Diagnostic Tool for Prostate Cancer Detection
Stroke Recovery Program-Cardiac Rehabilitation of Stroke Survivors
Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery
OBWELL: Evaluating the Effectiveness of an Innovative Psychotherapeutic Intervention to Treat Postpartum Depression Among High-Risk Mothers
LEAD Pilot Study: Leveraging the Emergency Department to Address SDOH and Reduce Lung Cancer Screening Disparities
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)